AbbVie Inc. logo

AbbVie (ABBV) stock

ABBV · AbbVie Inc. · NYSE

$286.42+2.84 (+1.00%)today
Website
Market cap
$506.27B
P/E
49.3
EPS (TTM)
$5.81
Shares out
1.77B
Open
$286.74
Prev close
$283.57
VWAP
$287.95
52-week range85% up the range
$191.33$302.85

Today $284.88 - $290.23

What is the latest news on ABBV stock?

ABBV rose 1.00% to $286.42 on Nov 20, 2026. No ABBV story in the last two days; the most recent is below.

PRago
AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference

NORTH CHICAGO, Ill., Nov. 20, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026. Management will participate in a fireside chat at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key th

All ABBV news
Price$286.42+24.52 (+9.36%)
2026-08-202026-11-20

When does AbbVie report earnings?

AbbVie last reported on Oct 30, 2026, the date it announced on Oct 1, 2026. Before that it reported on Jul 31, 2026 and Apr 29, 2026. On that schedule the next report would come around late January 2027, with the date usually announced about 4 weeks ahead.

ABBV earnings history

Who owns the most ABBV stock?

BlackRock, Inc. was the largest reported holder of ABBV at the end of Q2 2026, with 149,488,412 shares worth $37.6 billion. Next came Vanguard Capital Management LLC ($29.0 billion) and State Street Corp ($20.8 billion). In all, 4,210 institutions reported $336.0 billion of ABBV in their 13F filings.

All ABBV fund holders

Are insiders buying or selling ABBV?

Insiders are selling. In the last 90 days 1 insider sold $11.9 million of ABBV in trades reported on Form 4. The latest: Jeffrey Ryan Stewart sold $11.9 million, reported on Nov 12, 2026.

ABBV insider trades

Financial highlights

Full financials
Revenue, TTM
$66.01B
Revenue growth
+10.7%
Net income, TTM
$10.34B
Net margin
15.7%
Free cash flow, TTM
$18.87B
Cash
$10.77B

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

ABBV rankings

News · 26 weeks115-67%
2026-05-31: 22026-06-07: 22026-06-14: 52026-06-21: 102026-06-28: 82026-07-05: 32026-07-12: 22026-07-19: 02026-07-26: 52026-08-02: 92026-08-09: 32026-08-16: 52026-08-23: 12026-08-30: 72026-09-06: 22026-09-13: 52026-09-20: 42026-09-27: 102026-10-04: 22026-10-11: 42026-10-18: 92026-10-25: 92026-11-01: 42026-11-08: 22026-11-15: 22026-11-22: 0
2026-05-312026-11-22
Mix6190d
  • Other47(77%)
  • SEC Filings6(10%)
  • Insider5(8%)
  • Earnings2(3%)
  • Dividends1(2%)
Activity · 52 weeks240129 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on ABBV

AbbVie Inc. (ABBV) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 19 wire items for ABBV, including 12 press releases and news items, 3 insider trades and 3 SEC filings. The most recent was published Nov 20, 2026.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

ABBV FAQ

10 questions
  • What does AbbVie Inc. do?
    AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...
  • What is ABBV revenue?
    AbbVie Inc. (ABBV) reported $66.01B of revenue for the twelve months ended Sep 30, 2026. That is up 10.7% from the year before. Revenue for fiscal 2025 was $61.16B.
  • Is ABBV profitable?
    Yes. AbbVie Inc. earned $10.34B in net income for the twelve months ended Sep 30, 2026, a net margin of 15.7%.
  • How much cash and debt does ABBV have?
    AbbVie Inc. reported $10.77B in cash and cash equivalents and $72.23B of debt on its most recent balance sheet in SEC filings.
  • Where does ABBV stock trade?
    AbbVie Inc. (ABBV) is listed on NYSE.
  • What sector and industry is ABBV in?
    AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did AbbVie Inc. go public?
    AbbVie Inc. (ABBV) completed its IPO in 2012.
  • What are analysts saying about ABBV?
    Across the last 8 analyst actions on AbbVie Inc., there were 3 upgrades and 1 downgrade. The most recent action was from Wolfe Research: Outperform with a $300.00 price target on 2026-08-13. Recent price targets range from $234.00 to $300.00.
  • What companies are similar to ABBV?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), REGN (Regeneron Pharmaceuticals Inc.), PFE (Pfizer Inc.), LLY (Eli Lilly and Company). Compare ABBV side-by-side with any of them on Quantisnow.
  • How can I track ABBV on Quantisnow?
    Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change